Article
Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer | 2 Minute Medicine
Rating:
0.0
Views:
54
Likes:
1
Library:
1
- Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival is longer in patients on mFOLFIRINOX compared to gemcitabine. Evidence Rating Level: 1 (Excellent) Study Rundown: One of the leading causes of cancer-related deaths globally is pancreatic ductal adenocarcinoma (PDAC). It has been shown that
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value